UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer

British journal of cancer, 2008-12, Vol.99 (12), p.2006-2012

2008

Volltextzugriff (PDF)

Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer

Annals of oncology, 2019-11, Vol.30 (11), p.1813-1820

2019

Volltextzugriff (PDF)

CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer

Annals of oncology, 2016-04, Vol.27 (4), p.654-660

2016

Volltextzugriff (PDF)

Relationship between apalutamide (APA) exposure and metastasis-free survival (MFS) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from SPARTAN

Annals of oncology, 2018-10, Vol.29, p.viii278-viii278

2018

Volltextzugriff (PDF)

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

The New England journal of medicine, 2015-11, Vol.373 (19), p.1814-1823

2015

Volltextzugriff (PDF)

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer

The New England journal of medicine, 2018-04, Vol.378 (15), p.1408-1418

2018

Volltextzugriff (PDF)

The immune response to breast cancer, and the case for DC immunotherapy

Cytotherapy (Oxford, England), 2004-04, Vol.6 (2), p.154-163

2004

Volltextzugriff (PDF)

Comparison of in situ methods to assess DNA cleavage in apoptotic cells in patients with breast cancer

Journal of clinical pathology, 1998-01, Vol.51 (1), p.34-37

1998

Volltextzugriff (PDF)

488PCorrelation of progression free survival-2 and overall survival in solid tumours

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Continuous infusional topotecan in advanced breast and non-small-cell lung cancer: no evidence of increased efficacy

British journal of cancer, 1997, Vol.76 (12), p.1636-1639

1997

Volltextzugriff (PDF)

Differential responses to chemoimmunotherapy in patients with metastatic malignant melanoma

European journal of cancer (1990), 1997-08, Vol.33 (9), p.1388-1392

1997

Volltextzugriff (PDF)

843OApalutamide (APA) and overall survival (OS) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Updated results from the phase III SPARTAN study

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

806PRelationship between apalutamide (APA) exposure and metastasis-free survival (MFS) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from SPARTAN

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

FIRSTANA: Health-related quality of life (HRQL) and post-hoc analyses for the phase III study assessing cabazitaxel (C) vs docetaxel (D) in chemotherapy-naïve patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Annals of oncology, 2016-10, Vol.27, p.vi245-vi245

2016

Volltextzugriff (PDF)

Abstract P1-15-21: The molecular characterisation of early and advanced breast cancer in a Middle-Eastern breast cancer cohort treated with neo/adjuvant anthracycline+/-taxane-based chemotherapy

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P1-P1-15-21

2019

Volltextzugriff (PDF)

A phase II study of dose-dense chemotherapy (doxorubicin (A), cyclophosphamide (C), paclitaxel (T), gemcitabine (G)) supported by pegfilgrastim (P) and darbepoetin-alfa (D) for patients with high-risk early stage breast cancer (ICANDO)

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.11068-11068

2007

Volltextzugriff (PDF)

Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer

Annals of oncology, 2019-11, Vol.30 (11), p.1813

2019

Volltextzugriff (PDF)

Ixabepilone and lapatinib for HER2-positive advanced breast cancer: Preclinical rationale and phase I trial

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.2582-2582

2009

Volltextzugriff (PDF)

Severe vascular adverse effects with thrombocytopenia and renal failure following emetogenic chemotherapy and ondansetron

Annals of oncology, 1994-01, Vol.5 (1), p.98-98

1994

Volltextzugriff (PDF)

A multicenter, open-label phase Ib/II study to assess the safety and clinical activity of intravenous combretastatin A1 diphosphate (OXi4503) as monotherapy in subjects with primary or secondary hepatic tumor burden

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.TPS164-TPS164

2010

Volltextzugriff (PDF)

Phase 1a safety and pharmacokinetic study of oral NV-196 in patients with solid tumours

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.14615-14615

2008

Volltextzugriff (PDF)

Cabazitaxel vs docetaxel in chemotherapy-naive (CN) patients with metastatic castration-resistant prostate cancer (mCRPC): A three-arm phase III study (FIRSTANA)

JOURNAL OF CLINICAL ONCOLOGY, 2016, Vol.34 (15_suppl), p.5006-5006

2016

Volltextzugriff (PDF)

Abstract P4-05-16: Quality metric study of real-time targeted massive parallel sequencing (MPS) (ampliseq comprehensive cancer panel (CCP)) and bioinformatics in early breast cancer (EBC) using life technologies ion proton system

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P4-P4-05-16

2013

Volltextzugriff (PDF)

Phase II study of docetaxel with or without plinabulin (NPI-2358) in patients with non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.7592-7592

2010

Volltextzugriff (PDF)

Randomized phase III study of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis by tumor epidermal growth factor receptor (EGFR) staining

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.3565-3565

2010

Volltextzugriff (PDF)

1 – 25 von 95

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(88)
Mit Volltextzugriff
(88)

Publikationsform

Sprache

Englisch
(94)

Erscheinungsjahr

n.n

Thema

Science & Technology
(51)
Humans
(41)
Life Sciences & Biomedicine
(40)
Male
(28)
Female
(26)
Middle Aged
(21)
Aged
(20)
Biological And Medical Sciences
(19)
Medical Sciences
(18)
Oncology
(18)
Adult
(16)
Chemotherapy
(13)
Tumors
(12)
Double-Blind Method
(11)
General & Internal Medicine
(10)
Medicine, General & Internal
(10)
Aged, 80 And Over
(9)
Disease-Free Survival
(9)
Animals
(8)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer

Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer

CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer

Relationship between apalutamide (APA) exposure and metastasis-free survival (MFS) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from SPARTAN

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer

The immune response to breast cancer, and the case for DC immunotherapy

Comparison of in situ methods to assess DNA cleavage in apoptotic cells in patients with breast cancer

488PCorrelation of progression free survival-2 and overall survival in solid tumours

Continuous infusional topotecan in advanced breast and non-small-cell lung cancer: no evidence of increased efficacy

Differential responses to chemoimmunotherapy in patients with metastatic malignant melanoma

843OApalutamide (APA) and overall survival (OS) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Updated results from the phase III SPARTAN study

806PRelationship between apalutamide (APA) exposure and metastasis-free survival (MFS) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from SPARTAN

FIRSTANA: Health-related quality of life (HRQL) and post-hoc analyses for the phase III study assessing cabazitaxel (C) vs docetaxel (D) in chemotherapy-naïve patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Abstract P1-15-21: The molecular characterisation of early and advanced breast cancer in a Middle-Eastern breast cancer cohort treated with neo/adjuvant anthracycline+/-taxane-based chemotherapy

A phase II study of dose-dense chemotherapy (doxorubicin (A), cyclophosphamide (C), paclitaxel (T), gemcitabine (G)) supported by pegfilgrastim (P) and darbepoetin-alfa (D) for patients with high-risk early stage breast cancer (ICANDO)

Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer

Ixabepilone and lapatinib for HER2-positive advanced breast cancer: Preclinical rationale and phase I trial

Severe vascular adverse effects with thrombocytopenia and renal failure following emetogenic chemotherapy and ondansetron

A multicenter, open-label phase Ib/II study to assess the safety and clinical activity of intravenous combretastatin A1 diphosphate (OXi4503) as monotherapy in subjects with primary or secondary hepatic tumor burden

Phase 1a safety and pharmacokinetic study of oral NV-196 in patients with solid tumours

Cabazitaxel vs docetaxel in chemotherapy-naive (CN) patients with metastatic castration-resistant prostate cancer (mCRPC): A three-arm phase III study (FIRSTANA)

Abstract P4-05-16: Quality metric study of real-time targeted massive parallel sequencing (MPS) (ampliseq comprehensive cancer panel (CCP)) and bioinformatics in early breast cancer (EBC) using life technologies ion proton system

Phase II study of docetaxel with or without plinabulin (NPI-2358) in patients with non-small cell lung cancer (NSCLC)

Randomized phase III study of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis by tumor epidermal growth factor receptor (EGFR) staining

Suchergebnisse filtern